Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis is supported by a differentiated genomics platform that sequences 20,000 genes across DNA and RNA while also measuring immune response in tissue and blood, giving it a broader data advantage than many precision oncology peers and positioning it to serve a large estimated $35B TAM across biopharma services and clinical diagnostics. Its fundamentals are being reinforced by meaningful commercial traction, including Q1'26 molecular clinical test volume of 7,815 (+258% Y/Y), Q1'26 diagnostic revenue of $1.4M, 2026 revenue guidance of $78-80M with $55-56M expected from pharma and $10-11M from diagnostics, and reaffirmed 2026 gross margin guidance of 15-20%, all while it held $233M of cash at the end of Q1'26. The outlook is further strengthened by expanding Medicare reimbursement, rising NeXT Personal MRD adoption, plans to grow the direct sales force from ~10 reps to ~15-20, and strategic validation from takeover interest and acquisition discussions, which together suggest increasing commercial leverage and improving long-term monetization of its technology.

Personalis is viewed negatively because its core growth drivers remain highly uncertain, with reimbursement for its MRD test potentially falling below expectations and NeXT Personal still dependent on additional MolDx approval and VA MVP task orders, while its biopharma business faces order-timing volatility and possible weakening demand from large pharma for personalized cancer vaccine development. The company’s near-term strength, including above-consensus 2Q26 revenue of $22.4M versus $16.8M consensus and 33% sequential test-volume growth, is overshadowed by the fact that it has agreed to be acquired by Tempus AI for $1.5B in a stock-heavy deal at only a 6% premium to the prior close, suggesting limited standalone confidence in sustained value creation. Even the bullish thesis requires biopharma sustaining more than 25% CAGR and stronger clinical diagnostics growth, underscoring that Personalis’s long-term outlook depends on several execution- and coverage-sensitive catalysts that may not materialize.